[Difficulties attendant on intracutaneous tuberculin tests in BCG-vaccinated persons (author's transl)].
Explore the source record for details and available documents.
Adolescent↗
SEARCH · Search PubMed
Results for “personalized vaccines”
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
[Smallpox immunity in repeatedly vaccinated persons].
Explore the source record for details and available documents.
Humans↗
Comparative study on antibody determination by different methods in sera of persons vaccinated with HDCS rabies vaccine.
The comparative studies undertaken by 7 laboratories in 6 countries show that the calculation of I.U.'s did not, as anticipated, minimize but actually enhanced the variability of results of rabies antibody estimations in the sera of HDCS vaccinees. The high biological variance in the method(s) may not have been considered by individual laboratories and any neglect of fundamental biostatistical laws unfortunately diminishes the theoretical advantage of using the "International Standard (I.S.)" as a "tertium comparationis". Perhaps the intrinsic variability of the I.S. should be re-evaluated and it is conceivable that a pure IgG fraction of rabies antiserum would show less variability. Intralaboratory variation might be reduced by agreeing that only a geometric mean of the I.S., and not a single value obtained in an individual test, should be used for calculation of I.U.'s. Application of the principles of biochemical and pharmacological methods, such as test-to-test control of the I.S. and its analytical variances might well enhance the reproducibility of the results. MNT, RFFIT, PRT and CFT were unable to detect antibodies in HDCS vaccinees until 7 days after the first vaccination. The establishment of methods for detecting early antibody requires further investigation.
Analysis of Variance↗
Comparative study on antibody determination by different methods in sera of persons vaccinated with HDCS-vaccine.
The comparative studies undertaken by 7 laboratories in 6 countries show that the calculation I.U.s did not as anticipated minimize but actually enhanced the variability of results of Rabies antibody estaminations in the sera of HDCS vaccines. The high biological variance in the method(s) may not have been considered by individual laboratories and any neglect of fundamental biostatistical laws, unfortunately, diminishes the theoretical advantage of using the "International Standard (I.S.)" as a "tertium comparationis". Perhaps the intrinsic variability of the I.S. should be re-evaluated and it is conceivable that a pure IgG fraction of Rabies antiserum would show less variability. Intralaboratory variation might be reduced by agreeing that only a geometric mean of the I.S., and not a single value obtained in an individual test, should be used for calculation of I.U.s. Application of the principles of biochemical and pharmacological methods, such as test-to-test control of the I.S. and its analytical variances might well enhance the reproducibility of the results. MNT, RFFIT, PRT and CFT were unable to detect antibodies in HDCS vaccinees until 7 days after the first vaccination. The establishment of methods for detecting early antibody requires further investigation.
Antibodies, Viral↗
[Response of the body to smallpox vaccination in persons with repeated negative vaccinal antecedents].
A study was carried out on the humoral response and vaccinal reaction after repeated administration of the smallpox vaccine (1 to 3 times), at ten days interval, to 97 subjects with a past history of repeated vaccination failures. Revaccination ended in 52.6% failures. After revaccination the antibody titer increased in 97.8% of the cases of successful vaccination and in 43.5% of the negative cases. In 29.5% of the latter cases a decrease in the antibody titer by 1--3 binary dilutions was found. The results suggest that the repeated application at short intervals of an antigenic stimulus perturbs the immune response.
Adult↗
[Construction of new types of chemical vaccines for the prevention of intestinal infections, and their qualitative assessment. IV. Physical properties and immunological characteristics of the experimental series of chemical vaccines presented for comparative study].
The authors present the results of study of physico-chemical properties of the chemical sorbed monovaccines from the antigens of the causative agents of typhoid fever, paratyphoid A and B and Sonne and Flexner dysentery obtained by various methods; the results of investigation of their reactogenic properties and immunological activity of limited groups of volunteers also given. The vaccines from the antigens obtained by sparing methods were less reactogenic than the rest experimental and control vaccines obtained from the tryptic antigens. The majority of the experimental vaccines caused a significant increase of the specific antibody titres in the sera of the vaccinated persons: typhoid vaccines--of the O-, VI- and H-antibodies, paratyphoid B vaccines--of the O- and H-antibodies; the control vaccines from the tryptic antigens failed to induce the H-antibody synteisis in the vaccinated persons. Experimental dysentery monovaccines induced a greater increase in the antibody titres than the control vaccines.
Antibodies, Bacterial↗
Artificial intelligence for translational personalized neoantigen cancer vaccine development.
Personalized neoantigen cancer vaccine is a promising strategy for precision immunotherapy by targeting patient-specific and mutation-derived tumor antigens. Early clinical studies have demonstrated the feasibility, safety, and immunogenicity of these vaccines across multiple solid tumors, with encouraging outcomes particularly when combined with immune checkpoint blockade. However, broader clinical translation remains limited by sequential bottlenecks across the vaccine development pipeline, including false-positive neoantigen selection,  imperfect modeling of antigen processing and HLA presentation, limited prediction of T-cell receptor recognition, and challenges in formulation, delivery, and manufacturing. Artificial intelligence and advanced computational workflows are increasingly integrated into this pipeline to improve candidate prioritization and support more reproducible decision-making. In this review, we summarize clinical progress and key translational barriers in personalized neoantigen vaccination, and discuss how AI-enabled approaches may contribute across four major stages: multi-omics integration for neoantigen discovery, processing-aware HLA presentation prediction, structure-aware and TCR-informed immunogenicity modeling, and data-driven formulation optimization, particularly for lipid nanoparticle-based delivery systems. These approaches are able to help narrow biological and chemical search spaces, improve prioritization, and provide mechanistic insights into antigen presentation and immune recognition rather than replacing experimental validation. This articlefurther addresses future implementation challenges, including dataset diversity, model interpretability, prospective benchmarking, manufacturing traceability, and evolving regulatory frameworks for individualized mRNA cancer immunotherapies. Integrating computational innovation with rigorous immunological validation, scalable manufacturing, and regulatory oversight will be essential for advancing personalized neoantigen vaccines toward broader clinical implementation.
Cancer Vaccines↗
Immunoinformatics Approach for Optimization of Targeted Vaccine Design: New Paradigm in Clinical Trials and Healthcare Management.
INTRODUCTION: The immunoinformatics approach combines bioinformatics and computational tools, offering a revolutionary method for improving vaccine development by analyzing immune responses at the molecular level. Immunoinformatics enables the creation of customized vaccines designed for specific infections or cancer cells. OBJECTIVE: The primary objective of immunoinformatics is to enhance the vaccine development process by predicting and boosting the body's immune response. It aims to identify potential immunogenic epitopes and biomarkers that are important for creating vaccines with greater specificity and efficacy, especially when dealing with large-scale data. METHODS: Immunoinformatics utilizes a combination of proteomic, genomic, and epigenomic data, as well as machine learning algorithms and artificial intelligence techniques. These tools predict how various immunological components, e.g., T-cell and B-cell epitopes, interact with the immune system. This approach allows researchers to avoid traditional trial-and-error methods, enabling the efficient identification of potential vaccine candidates. Additionally, personalized vaccines can be developed by considering individual genetic and immunological characteristics. RESULTS: The use of immunoinformatics techniques accelerates the screening of vaccine candidates, enhances patient stratification, and optimizes formulations for clinical trials. This approach has been shown to improve vaccine safety, efficacy, and development speed. It also holds promise for managing healthcare on a large scale by producing vaccines tailored to specific populations, thereby improving the overall effectiveness of vaccination programs. CONCLUSION: Immunoinformatics represents a transformative approach to vaccine research, improving clinical trial efficiency and enabling the development of more reliable, flexible, and personalized vaccines. This approach has the potential to significantly enhance global healthcare outcomes by accelerating the vaccine development process and optimizing vaccination strategies.
Immunoinformatics↗
Autoantibodies in human sera after vaccination with inactivated influenza vaccine.
Sera from persons vaccinated with inactivated bivalent influenza vaccine were tested for the presence of smooth-muscle antibodies (SMA) and antibodies against the brush border of proximal renal tubuli (ABBA). The autoantibodies were found with the highest frequency in persons repeatedly vaccinated with the vaccine.
Antibodies, Viral↗
A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer Vaccine and Therapy.
Nanovaccines co-assemble antigens and adjuvants to elicit robust immune responses but often require complex synthesis and post-modification procedures. Here, a programmable nanovaccine platform based on the M13 bacteriophage is developed for the scalable production of vaccines and single-step modular engineering of adjuvanticity, length, and antigen density. By reprogramming the sequence and size of the noncoding phage genome, the Toll-like receptor 9 activation and the length of the phage are precisely controlled. With a novel molecular engineering approach, the antigen density is tuned from 13.6% to 70.3%. A systematic modulation reveals an optimal adjuvanticity at a constant antigen density for maximum anti-tumor CD8+ T cell response, and vice versa, using the model antigen SIINFEKL. The M13 phage-based nanovaccine induces durable memory immunity lasting over a year. In addition, a 24-fold increase in neoantigen-specific CD8+ T cell frequency is achieved when increasing both the adjuvanticity and antigen density. Furthermore, when combined with anti-PD-1 therapy, the M13 phage-based personalized vaccine eradicates established MC-38 tumors in 75% of treated animals and they develop 100% resistance against tumor invasion when challenged 5 months after treatment. These findings establish M13 phage as a powerful and versatile nanovaccine platform with transformative potential for personalized cancer immunotherapy.
Cancer Vaccines↗
[Comparative study of the smallpox vaccines from B-51, EM-63 and L-IVP in a controlled epidemiological experiment. II. The characteristiics of the immunogenicity of the smallpox vaccines].
Immunogenicity of smallpox vaccines prepared of EM-63, L-IVP, and B-51 strains was studied under conditions of strict controlled epidemiological trial. Skin reactions to revaccination and vaccines antigenic activity indices were detemined in the persons vaccinated. Changes in the virus-neutralizing and antibodies suppressing hemagglutination was the same in persons vaccinated with any of the preparations tested. The maximal virus-neutralizing antibodies level was determined 1 month after the vaccination and persisted without any essential changes for one year. The titre of hemagglutination inhibiting antibodies also reached the maximum in one month, but diminished gradually by the end of one year after the vaccination. There were found no significant differences in the antigenic activity of the vaccines. The vaccines studied also displayed no difference in the number and character of skin reactions to revaccination. In comparing the antibodies level and the character of skin reactions to revaccination it was found that the titres of hemagglutination inhibiting antibodies and virus-neutralizing antibodies of 1:40 and over were in the great majority of cases determined in the blood sera of the vaccinated persons with the immediate and negative reactions to revaccination, i. e. in those with intensive postvaccinal immunity.
Antibodies, Viral↗
Beyond Canonical Neoantigens: Emerging Technologies for Identification of Noncanonical Antigens and Implications for Personalized Cancer Vaccines.
Over the past decade, advances in sequencing technologies and computational pipelines enabled the development of personalized cancer vaccines (PCVs). Current PCV strategies primarily target cancer neoantigens generated by non-synonymous DNA mutations, which can result in altered amino acid sequences capable of eliciting tumor-specific immune responses. More recently, a distinct class of tumor-specific antigens (TSA), termed noncanonical or cryptic antigens, has emerged as an additional source of immunogenic targets. Unlike canonical neoantigens, noncanonical antigens typically cannot be identified by tumor/normal whole-exome sequencing, as they do not arise from classical DNA mutations. Instead, they are often associated with less well recognized and/or aberrant processes in the pathways from DNA to human leukocyte antigen (HLA)-presented peptides. Examples include transposable elements, circular RNA, translation of alternative open reading frames and/or long non-coding RNA, among others. Emerging evidence suggests that noncanonical antigens represent a substantial portion of the tumor-specific immunopeptidome and, similar to canonical neoantigens, are absent during thymic selection and can evade central tolerance and elicit T cell responses. Technological advances have increasingly facilitated the identification of noncanonical antigens. Long-read RNA sequencing reveals noncanonical transcripts by improving transcriptome assembly, while ribosome profiling provides genome-wide maps of actively translated regions, facilitating the discovery of peptides from aberrant translation events. Specialized molecular approaches enable enrichment and sequencing of circular RNAs, and immunopeptidomics using mass spectrometry allows for direct characterization of HLA-presented peptides. Together, these technological advances have led to an increasing interest in prioritizing and targeting noncanonical antigens in the next generation of PCVs. This review provides an overview of the diverse origins of TSAs beyond classical neoantigens and discusses emerging approaches that may enable the integration of these antigens in future clinical trials.
circular RNA↗
[Findings concerning characteristics of responses to administration of vaccines containing antigenic complexes of enteric bacteria and tetanus toxoid].
Forty eight hours after the immunization with vaccines containing antigenic complexes of typhoid-paratyphoid and dysentery bacteria (0.65--1 mg of the antigens per vaccination dose) some of the persons vaccinated displayed an increase in the leukocyte count chiefly on account of the neutrophil forms and monocytes, a moderate elevation of bilirubin, asaraginamino-transferase and glutamic dehydrogenase in the serum; there was also some reduction of serum cholesterol, the appearance of cylinders and of protein traces in the urine, as well as ECG changes. The noted changes were of short duration and were not recorded in later examinations. The persons vaccinated presented no complains 24 hours, 2, 3, and 9 days after the vaccination and completely retained their working capacity.
Adult↗
Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.
Pancreatic ductal adenocarcinoma (PDAC) is unresponsive to standard immunotherapies despite harboring cancer neoantigens capable of eliciting T cell responses. We completed two phase 1 clinical trials (NCT03956056 and NCT03122106) evaluating safety and immunogenicity of synthetic long peptide (SLP) and DNA personalized cancer vaccines (PCVs). PCVs were administered after resection and adjuvant chemotherapy. Tumor/normal whole-exome sequencing, RNA sequencing, and pVACtools were used to identify and prioritize candidate PCV neoantigens. PCVs were well tolerated without any grade ≥3 adverse events. Neoantigen-specific responses were demonstrated by interferon-γ enzyme-linked immunospot and intracellular cytokine staining. Expanded T cell receptor clonotypes were sequenced and transduced into autologous peripheral blood mononuclear cells to confirm neoantigen specificity. When compared with a contemporaneous institutional propensity-matched cohort, PCV patients demonstrated a trend toward prolonged median overall survival (4.4 versus 3.5 years, log-rank P = 0.23). Overall, PDAC PCVs are safe and feasible and elicit polyclonal T cell responses, linking prioritized cancer neoantigens to functional antitumor immunity.
Humans↗
[Reactogenicity and immunologic activity of live enteric Sonne dysentery vaccine from a spontaneous mutant].
Live dysentery Sonne vaccine from a spontaneous mutant proved to be practically areactogenic and specifically harmless in oral immunization of children aged from 7 to 13 years, in doses of from 3 to 25 milliard live microbial cells and in single and triple immunization schemes. Weak reactions of the gastro-intestinal tract were noted with the same frequency (1.7%) in children immunized with the vaccine and in children given placebo (2.2%). There proved to be a significant increase in the serum of the immunized persons of the level of specific hemagglutinins, and also of the IgA-and IgM-titers in 82% of the persons vaccinated; they persisted at a high level for 2 months. The appearance of IgA-antibodies in high titres in the persons vaccinated orally pointed to a marked local and general immunological activity of the live dysentery Sonne vaccine from the spontaneous mutant processing the capacity to survive in the intestine of children for a long time.
Adolescent↗
[Reaction to influenza vaccine in persons with different conditions of the palatine tonsils].
Explore the source record for details and available documents.
Chronic Disease↗
[Experience in using inactivated influenza vaccine with persons at "high risk"].
Explore the source record for details and available documents.
Adsorption↗
[Therapeutic and preventive vaccination of persons bitten by wolves in the Aktiubinsk region].
A total of 46 cases of wolves attacking people were registered in the Aktyubinsk region during the period of 1972--1976. These attacks resulted in 1 person dying of wounds and 2 persons being infected with rabies. In more than a half of the wolves available for examination after the attack rabies was confirmed by laboratory investigation. All the victims of such attacks received antirabies gamma globulin (0.25--0.5 ml per kg body weight) and the maximum doses of rabies vaccine (daily injections of 5 ml for 25 days, then 2 more injections in the same dose 10 and 20 days later). No complications were observed after the injections. The vaccination schedule recommended for use in the USSR for the prophylaxis of rabies proved to be effective.
Adolescent↗